arrow
B

Brett Hughes

Royal Brisbane & Women's Hospital
H指数:46
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC)-A Phase 1B/2 Trial

POPCORN研究临床结果:非小细胞肺癌(NSCLC)中术前PD1检查点阻滞和NF-κB配体受体激活剂(RANKL)抑制的药效学——一项1B/2期临床试验

2026-01-010
OA
Comparison of Prophylactic Versus Reactive Tube Feeding Approaches on Weight Loss and Unplanned Hospital Admissions in Patients with Head and Neck Cancer Receiving Chemoradiotherapy

头颈癌接受放化疗患者中,预防性与反应性管饲喂养方法对体重减轻和非计划性住院的影响比较

2025-12-210
OAAI
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis

PD-L1对EGFR突变型NSCLC一线奥希替尼疗效的影响:AURORA25研究真实世界数据与荟萃分析

2025-11-240
PRE
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma

健康相关生活质量结局:来自KEYNOTE-412的研究——头颈鳞状细胞癌患者接受含或不含有pembrolizumab的化疗与放疗联合治疗的结果

2025-10-060
OAAI
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

索托拉西布与多西他赛在经治KRAS G12C突变型晚期非小细胞肺癌中的颅内活性比较:一项全球性、III期、随机对照试验

2025-07-290
OAAI
Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response
2025-02-120
OAAI
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC An Open-Label Phase 2 Trial (ILLUMINATE)

Durvalumab,Tremelimumab和铂类化疗在EGFR突变阳性NSCLC中的应用开放标签2期试验 (illumate)

2025-02-010
OA
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWERCSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
2025-01-013
PRE
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
2024-07-010
OA